Skip to main content
. Author manuscript; available in PMC: 2014 Jul 15.
Published in final edited form as: Clin Cancer Res. 2013 May 20;19(14):3844–3855. doi: 10.1158/1078-0432.CCR-13-0505

Fig 3. CD16x33 BiKE triggers NK cell degranulation and cytokine production against de-novo CD33+ AML targets, an effect that is enhanced by ADAM17 inhibition.

Fig 3

Purified NK cells isolated from healthy donors (n=6) were cultured with de-novo CD33+ AML cells (E:T ratio of 2:1). Cells were treated with or without 5 ug/mL of CD16x33 BiKE and with or without 2uM of an ADAM17 inhibitor (INCB003619). (A) Representative flow cytometry analysis of CD56+ NK cells after 4 hours in culture. Aggregate data of (B) intracellular CD107a degranulation, TNF-α, and IFN-γ for the indicated conditions and (C) CD16 expression (baseline CD16 expression of NK cells shown in the dotted line) (n=6, *P<0.05; **P<0.01, ***P<0.001).